Back to Authors

Sanghavi, Devang

https://orcid.org/0000-0003-4742-8963

Mayo Clinic

Mayo Clinic

Citations 97

Bivalirudin resistance in a patient on veno-venous extracorporeal membrane oxygenation with a therapeutic response to argatroban
Berlioz, Beric E. , Kaseer, Haya , Sanghavi, Devang , Berlioz, Beric, Kaseer, Haya S , Sanghavi, Devang K., Berlioz, Beric E. , Guru, Pramod

BMJ Case Reports | January 8, 2020 | Volume: 13 | Issue: 1 | Pages: e232262

10.1136/bcr-2019-232262 Get It

A 48-year-old male patient requiring extracorporeal membrane oxygenation (ECMO) support for hypoxaemic respiratory failure failed to achieve therapeutic anticoagulation with bivalirudin after continuous dose escalations, and continued to have recurrent fibrin stranding in the circuit over a 6-day course of treatment. Suspecting bivalirudin resistance, the patient was transitioned to argatroban and achieved a therapeutic response in less than 24 hours. The case describes the challenges of anticoagulation in ECMO supported patients. The interplay between bivalirudin metabolism, renal replacement therapy, and immunological effects leading to a heparin-like-effect, inflammatory mediators, and thrombotic burdens may all impact the clinical effect during bivalirudin therapy. The structural biochemistry of thrombin and bivalirudin likely plays a role in the presented patient’s successful response to argatroban. Bivalirudin may fail at achieving therapeutic anticoagulation in patients with genetic thrombin mutations or structural defects that alter the binding pockets at the thrombin exosites.
1705: ANGIOTENSIN II: ADJUNCTIVE THERAPY FOR REFRACTORY VASODILATORY SHOCK
Carmon, Stephanie, Matos, Nikki , Burnside, Rebecca, Sanghavi, Devang , Franco, Pablo Moreno

Critical Care Medicine | December 18, 2019 | Volume: 48 | Issue: 1 | Pages: 827-827

10.1097/01.ccm.0000649120.71040.58 Get It

921: EVALUATION OF HEPARIN VERSUS BIVALIRUDIN ANTICOAGULATION FOR EXTRACORPOREAL MEMBRANE OXYGENATION
Kaseer, Haya , Soto‐Arenall, Matthew, Sanghavi, Devang , Ratzlaff, Robert A. , Moss, John, Kaseer, Haya S , Guru, Pramod , Pham, Si M. , Moss, John E.

Critical Care Medicine | December 18, 2019 | Volume: 48 | Issue: 1 | Pages: 440-440

10.1097/01.ccm.0000633220.92412.3d Get It

529: SPONTANEOUS INFERIOR PHRENIC ARTERY RUPTURE IN A PATIENT WITH SUPRATHERAPEUTIC INR
Lewis, Kristyn, Cushenbery, Kristin, Sanghavi, Devang , Umadat, Goyal , Guru, Pramod

Critical Care Medicine | December 18, 2019 | Volume: 48 | Issue: 1 | Pages: 245-245

10.1097/01.ccm.0000620460.39265.30 Get It

270: A CASE OF LEFT ATRIOESOPHAGEAL FISTULA WITH SUBSEQUENT AIR EMBOLI
Carter, Laurel, Heckman, Alexander , Matos, Nikki , Sanghavi, Devang , Carter, Laurel E.

Critical Care Medicine | December 18, 2019 | Volume: 48 | Issue: 1 | Pages: 117-117

10.1097/01.ccm.0000619436.19115.8d Get It

Tumour-bowel fistula as a possible complication of pazopanib therapy in retroperitoneal leiomyosarcoma
Pereira, Rodrigo Otavio Lami , Patel, Payal R. , Sanghavi, Devang , Sanghavi, Devang K., Guru, Pramod

BMJ Case Reports | November 11, 2019 | Volume: 12 | Issue: 11 | Pages: e230727

10.1136/bcr-2019-230727 Get It

Pazopanib is a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR TKI) that inhibits the vascular endothelial growth factor receptor A pathway and has the potential to cause ischaemic bowel changes, including perforation. Here we report a case of a 51-year-old man with large, metastatic, retroperitoneal leiomyosarcoma that developed a tumour-bowel fistula after 4 weeks of pazopanib therapy. He presented to the emergency department with sepsis and 1-week history of worsening fever, chills, nausea and diarrhoea. Abdominal CT findings of mesenteric and portal vein gas, commonly found in mesenteric ischaemia and VEGFR modulator-induced bowel toxicity, provided evidence for the causal relation. Unfortunately, the case was not amenable to surgery and patient succumbed to the illness.
Impact of Telemedicine Monitoring of Community ICUs on Interhospital Transfers*
Pannu, Jasleen , Sanghavi, Devang , Sheley, Todd, Schroeder, Darrell R. , Marquez, Alberto , Brown, Daniel R. , Caples, Sean M., Kashyap, Rahul , Daniels, Craig , Schroeder, Darrell

Critical Care Medicine | May 6, 2017 | Volume: 45 | Issue: 8 | Pages: 1344-1351

10.1097/ccm.0000000000002487 Get It

Objectives: To study the effects of tele-ICU monitoring on interhospital transfers from community-based ICUs to the quaternary care hospital at Mayo Clinic, Rochester, MN. Design: This is a retrospective review of data on interhospital transfers comparing trends prior to tele-ICU implementation to those following implementation. Setting: Tele-ICU programs are increasingly utilized to fill resource gaps in caring for critically ill patients. How such programs impact population and bed management within a healthcare system are not known. Mayo Clinic serves as quaternary referral care center for hospitals in the region within the Mayo Clinic Health System. In August 2013, we implemented tele-ICU monitoring at six Mayo Clinic Health System hospital ICUs. Subjects: All adult ICU admissions during the study period (preimplementation phase: January 1, 2012, to December 31, 2012; and postimplementation phase: January 1, 2014, to December 31, 2014) in any of the six specified community ICUs were included in the study. Measurements and Main Results: Interhospital transfers significantly increased post institution of tele-ICU (p = 0.040) and was attributed primarily to transfer from less specialized ICUs (p = 0.037) as compared with more resource-intensive ICUs (p = 0.88). However, for such patient transfers, there were no significant differences before and after severity of illness scores, ICU mortality, or inhospital mortality. Conclusion: In a regional healthcare system, implementation of a tele-ICU program is associated with an increase in interhospital transfers from less resourced ICUs to the referral center, a trend that is not readily explained by increased severity of illness.